Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
    7.
    发明授权
    Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins 失效
    使用基于MMP-9和β1整联蛋白的拮抗剂抑制血管生成的方法和组合物

    公开(公告)号:US07566449B2

    公开(公告)日:2009-07-28

    申请号:US11089999

    申请日:2005-03-25

    CPC classification number: C07K16/2842 C07K2317/34

    Abstract: Antagonists for modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are described. Such antagonists inhibit angiogenesis, tumor growth and disease states. Example antagonists are polypeptide and non-polypeptide molecules, including the novel antibody Mab FM155 and the novel synthetic peptide FRIP-1. Methods for inhibiting angiogenesis and disease states by administering such antagonists are disclosed. Methods for identifying antagonists that modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are also described.

    Abstract translation: 描述了用于修饰涉及MMP-9和/或β1整联蛋白中某些氨基酸序列的蛋白质 - 蛋白质相互作用的拮抗剂。 这种拮抗剂抑制血管发生,肿瘤生长和疾病状态。 示例性拮抗剂是多肽和非多肽分子,包括新型抗体Mab FM155和新型合成肽FRIP-1。 公开了通过施用这种拮抗剂来抑制血管生成和疾病状态的方法。 还描述了用于鉴定修饰涉及MMP-9和/或β1整联蛋白中某些氨基酸序列的蛋白质 - 蛋白质相互作用的拮抗剂的方法。

    Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
    9.
    发明授权
    Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2 失效
    使用基于MMP-2内的序列的化合物抑制血管生成和肿瘤生长的方法和组合物

    公开(公告)号:US07019108B2

    公开(公告)日:2006-03-28

    申请号:US09872165

    申请日:2001-06-01

    CPC classification number: C12N9/6491 A61K38/00 C12Q1/37

    Abstract: The present invention provides methods and compositions for inhibiting angiogenesis, tumor growth and treating disease states using a peptide that contains a specific amino acid sequence of matrix metalloproteinase 2 (MMP-2). In one embodiment, the invention provides a peptide, which comprises the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. Additionally, the invention provides compositions for inhibiting angiogenesis or tumor growth or for treating disease states comprising organic and non-peptidic mimetics based on the above amino acid sequence as well as optimized sequences flanking the region of MMP-2 within which the sequence lies. Also provided are methods for detecting angiogenesis, tumorous tissue, metastases, and tumor invasion into a tissue by contacting a composition of the invention with a tissue and methods for screening compositions of the invention.

    Abstract translation: 本发明提供了使用含有基质金属蛋白酶2(MMP-2)的特定氨基酸序列的肽来抑制血管发生,肿瘤生长和治疗疾病状态的方法和组合物。 在一个实施方案中,本发明提供了一种肽,其包含氨基酸序列Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg,优选在氨基和羧基末端侧接半胱氨酸残基。 另外,本发明提供了用于抑制血管发生或肿瘤生长或用于治疗疾病状态的组合物,其包含基于上述氨基酸序列的有机和非肽模拟物以及序列所在的MMP-2区域侧翼的优化序列。 还提供了通过将本发明的组合物与组织接触并筛选本发明组合物的方法来检测血管生成,肿瘤组织,转移和肿瘤侵入组织的方法。

    CLK-peptide and SLK-peptide
    10.
    发明授权
    CLK-peptide and SLK-peptide 有权
    CLK-肽和SLK-肽

    公开(公告)号:US07662783B2

    公开(公告)日:2010-02-16

    申请号:US11251442

    申请日:2005-10-14

    CPC classification number: A61K38/08 A61K38/10

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法,其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长,肿瘤转移或再狭窄的方法,以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。 本发明还描述了使用所述拮抗剂结合放射疗法治疗肿瘤的方法和包括拮抗剂和放射治疗的疗法。

Patent Agency Ranking